The taste masking market is anticipated to grow at a steady pace till 2035, claims Roots Analysis Driven by the growing need to enhance palatability of oral drugs and drug adherence among pediatric and geriatric population, the demand for novel and advanced taste masking and taste assessment technologies is expected to rise in the coming years. London Roots Analysis has announced the addition of “Taste masking and Taste Assessment Services and Technologies Market, 2022-2035” report to its list of offerings. The inherent expertise of CMOs and CDMOs in taste masking and taste assessment of bitter drug formulations, along with capabilities to identify globally accepted tastes, develop flavor matching placebo formulations (for testing) having compliance with stringent regulatory guidelines and good clinical practices (GCPs) and proprietary technologies offering significant cost-benefits, have rendered outsourcing as a crucial aspect of taste masked formulation development and production. Key Market Insights Presently, 50 companies claim to offer taste masking and taste assessment services for oral drug formulations Majority (40%, each) of the service providers are based in North America and Europe, followed by companies headquartered in Asia-Pacific (18%). A large proportion (34%) of these companies are large players, followed by small (31%) and mid-sized firms (27%). Close to 30 technology platforms have been developed for taste masking and taste assessment of oral drug formulations Majority (68%) of the technology platforms are used for taste masking and taste assessment of solid oral formulations (tablets, capsules, granules and powder), followed by liquid (10%) oral formulations (suspensions, syrups and solutions). Partnership activity in this field has grown significantly between 2018 and 2021 The maximum number of partnerships were established in 2021 indicating a recent rise in the interest of players engaged in the field of taste masking and taste assessment. It is worth highlighting that majority of the agreements were related to acquisition, representing 46% of the total number of partnerships signed. This is followed by agreements signed for manufacturing of oral drug formulation (13%). More than 460 patents have been filed / granted for taste masking and taste assessment techniques and technologies, since 2017 Close to 60% of the patent applications have been filed by various industry and non-industry players in this domain post 2018. It is worth noting that, around 75% of the patents were filed / granted in the US, followed by European Patent Office (25%). North America is anticipated to capture larger share of the market by 2035 The taste masking market is likely to be driven by technology platforms that employ coating techniques. Further, solid formulations are likely to hold greater market share. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market/request-sample.html The report features inputs from eminent industry stakeholders, who were very optimistic concerning the need of outsourcing of taste masking and taste assessment services in the coming decade. The report includes detailed transcripts of the discussions held with the following industry experts:  Phillipe Tschopp (Head of Business Development, Glatt Pharmaceutical Services)  David Tisi (Director of Technical Operations, Senopsys)  Brandon Keener (Business Development Associate, Adare Pharma Solutions) For additional details, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com

The organ-on-chip market is anticipated to grow at a CAGR of 21.3% till 2035 In order to overcome the limitations and challenges related to animal testing, researchers and industry stakeholders are gradually adopting organ-on-chip products and technologies, which offer multiple benefits over conventional systems. Roots Analysis has announced the addition of “Organ-on-Chip Market, 2022-2035: Focus on Products and Technologies” report to its list of offerings. With the introduction of FDA Modernization Act in 2021, the use of animal models for preclinical testing is being discouraged in the pharmaceutical industry. Several players have opted to modernize their conventional testing models with organ-on-chip products and technologies. These novel products have the potential to transform the drug discovery process by simulating the human physiological and functional environment on a microfluidic system. In addition, these organ-on-chip models not only reduce the need for animal testing model but are also capable of speeding-up the research and precise evaluation of drug toxicity and cellular responses. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/organ-on-a-chip-market/request-sample.html Key Market Insights Around 145 organ-on-chip products and technologies are offered by 45+ players Nearly 67% of the aforementioned products and technologies are commercialized; of these, 93% products and technologies are intended for drug discovery and toxicity testing related applications, followed by cancer research (44%), stem cell research (32%) and tissue engineering and regenerative medicine (21%). 420+ patents related to organ on chip products and technologies were filed / granted, since 2017 Based on the intellectual property distribution across the world, R&D activity related to organ on a chip technology and product is largely concentrated in China (over 30%), followed by the US (24%). The majority of the patents in this domain were filed by non-industry players (55%). More than 345 grants have been awarded to support the ongoing research for organ-on-chip models Grants worth USD 167 million have been awarded to various companies / organizations working in this domain till July 2022. Further, the number of grants awarded to stakeholders in this domain (in the US) has continuously increased between 2019 and 2021. Around 20% of the grants were funded by the National Center for Advancing Translational Sciences. Partnership activity in this domain has increased at a significant pace, between 2017 and 2022 The maximum number of partnerships were established in 2020 and 2021 (21, each), indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that the majority of the deals were technology / product utilization agreements, representing around 30% of the total number of partnerships signed in the given time period. Amount worth over USD 680 million was invested by both private and public investors in this domain, since 2017 Of the total amount invested, around USD 385 million was raised through grants / awards, representing around 55% of the overall funding activity in this domain. Further, 13 instances of venture capital financing were also reported, wherein players collectively raised more than USD 215 million. North America and Europe are anticipated to capture over 75% of the market share by 2035 The market in Asia-Pacific and Rest of the World are anticipated to grow at a relatively faster rate to occupy overall 24% of the total market. In addition, it is worth noting that organ(s) based models are likely to capture more than 70% of the market. For additional details, please visit https://www.rootsanalysis.com/reports/organ-on-a-chip-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. 3D Cell Culture Market (4th Edition): Industry Trends and Global Forecast, 2022-2035 2. Artificial Intelligence in Oncology Market: Industry Trends and Global Forecast, 2022-2035 Contact: Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com

CAR-T CELL THERAPIES: ADDRESSING KEY UNMET NEEDS ACROSS VARIOUS ONCOLOGICAL INDICATIONS Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR-T cell therapy, a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. Overall, this highly specific and promising form of CAR-T cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html At present, more than 5 CAR-T therapies have been approved for several hematological malignancies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences), Breyanzi® (Bristol Myers Squibb), Abecma™ (Bristol Myers Squibb) and CARVYKTI™ (Janssen Biotech / Legend Biotech). In fact, more than 170 companies are engaged in the development of over 970 early and late-stage CAR-T therapies, worldwide. Moreover, several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. Over 6,500 patents related to CAR-T cell therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, more than 260 collaborations have been inked between several industry / academic stakeholders in order to advance the development of various pipeline candidates. To fund product development initiatives, capital investments worth more than USD 24 billion have been made by various private and public sector investors, in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the CAR-T cell therapy market is likely to witness significant growth in the foreseen future. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com

MANUFACTURING EXECUTION SYSTEM PROVIDERS IN HEALTHCARE MARKET Every year, the healthcare industry generates a massive amount of data. In fact, the healthcare data currently constitutes around 30% share of the global data volume. Further, it is estimated that, by 2025, the data generated via the healthcare sector will rise at a compound annual growth rate of 36%. It is important to consider that the constant management of such enormous volumes of data is a quite tedious process and challenging process. Specifically, management and handling of huge datasets in the healthcare industry often requires a large workforce of specialized personnel. According to the American Hospital Association, by 2026, there is likely to be a shortage of 3.2 million healthcare workers. The continuously growing data, coupled to the projected deficit of healthcare workers, would inadvertently generate pressure on healthcare manufacturers to adopt novel tools / technologies that can improve management efficiency and better utilize the available, expensive resources. Moreover, increasing complexity of healthcare manufacturing operations, along with growing stringency and frequent changes in regulatory requirements has created a dire need for adoption of automated solutions, such as manufacturing execution systems (MES). It is worth mentioning that, in the past few years, substantial acquisition activity has been reported in the manufacturing execution systems market, as players strive to become one-stop-shops, to cater to the diverse needs of the healthcare sector. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/manufacturing-execution-systems-market/request-sample.html In recent years, several healthcare stakeholders have actively undertaken initiatives to incorporate a manufacturing execution system into their production lines, with an aim to connect, monitor and control the complex manufacturing process. In addition, players are integrating advanced technologies, including internet of thing (IoT) and artificial intelligence (AI), in order to collect and analyze large volume of data from various sources, as well as to produce value in the form of insights, predictions and actions. According to industry experts, MES has the potential to reduce 10%-30% of the overall production cost depending on the type of industry. It has further been observed that companies are increasingly adopting cloud-based manufacturing execution system, to overcome the challenges associated with growing complexity of processes and global expansion of businesses. Specifically, cloud-based MES integrates real-time information of different production floors and promotes collaboration. Driven by the ongoing innovation in the industry, as well as the rise in demand for automated solutions, the manufacturing execution system providers market for the healthcare sector is likely to witness positive growth over the coming years. For additional details, please visit https://www.rootsanalysis.com/reports/manufacturing-execution-systems-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com

THE INTRICACIES ASSOCIATED WITH CELL THERAPY MANUFACTURING HAVE PAVED THE WAY FOR NOVEL AUTOMATION TECHNOLOGIES Over the years, several advanced and innovative automation tools and technologies have been developed; these have been demonstrated to hold the potential for significant reduction in the cost associated with the manufacturing of advanced therapy medicinal products, thereby, making such products more affordable. Considering the vast potential of cellular therapies in the treatment of rare disorders and sufficient body of evidence validating the clinical benefits / therapeutic potential of this complex class of biologic drugs, cell therapies have garnered considerable attention of players engaged in the healthcare industry, in the past few years. The focus of stakeholders has now shifted to optimizing the cell therapy manufacturing process. It is important to mention that we have forecasted the evolution of the overall cell therapy manufacturing market, focusing on T-cell immunotherapies, dendritic cell therapies, NK cell therapies and stem cell therapies. Considering the sufficient body of evidence validating the clinical benefits / therapeutic potential of this complex class of biologic drugs, the focus of stakeholders has now shifted to optimizing the cell therapy manufacturing process. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/285/request-sample.html One such emerging concept, namely GMP-In-A Box, offers several advantages, including increased throughput, decreased idle time between batch runs and reduced manual labor. However, the delicate nature of steps involved in the cell therapy production process is known to hinder the overall automation process. Further, the lack of specialized infrastructure and limited expertise available in this domain are some of the known challenges impacting the growth of this segment. Despite the challenges associated with the development and production of such therapies, we believe, that the benefits offered by them outweigh the hurdles. They are likely to serve as important drivers of the industry’s growth. Efforts to introduce automation technologies in cell therapy manufacturing are underway, and if implemented successfully, can significantly help in the elimination of human intervention and reduce the risk of contamination. As a consequence, it is likely to result in a marked increase in product consistency, ensure the maintenance of sterility, and decrease the production time and cost. In a nutshell, cell therapies are expected to soon represent one of the prominent therapeutic options within the mainstream healthcare. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com  

The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10% Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies. Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings. The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers. Key Market Insights Over 150 companies claim to offer companion diagnostics development services, globally Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers. Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers. Over 90 companies are actively involved in the development of companion diagnostics Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics. Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021 Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders. North America is expected to capture ~60% share in the companion diagnostics development services market by 2035 Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/297/request-sample.html One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com

The biopharmaceutical contract manufacturing market is projected to grow at a CAGR of 10% during 2022-2035, claims Roots Analysis With the advent of novel technologies and rising preference for such therapeutic interventions, biologics have made a significant impact in the pharmaceutical domain, delivering a ground-breaking treatment regimen for a myriad of disease indications. London Roots Analysis has announced the addition of the “Biopharmaceutical Contract Manufacturing Market, 2022–2035” report to its list of offerings. In pursuit of both time and cost savings, as well as to access higher scales of production, outsourcing has emerged as a lucrative option for biologic drug developers. Driven by several blockbuster products, a burgeoning pipeline of biologic drugs, the demand for reliable contract service providers, which have the required expertise and advanced manufacturing capabilities, is expected to grow at a commendable pace in the coming years. Currently over 275 companies claim to be biopharma CDMO / biopharma CMO, in compliance with the regulatory standards. It is also worth highlighting that biopharmaceutical contract manufacturers are actively trying to consolidate their presence in this field by entering into strategic alliances in order to meet the indubitably rising demand for biologics. In 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. However, biologics manufacturing is fraught with various challenges. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/250/request-sample.html Key Market Insights Presently, more than 275 players offer contract manufacturing services for biologics This segment of the industry is dominated by the presence of mid-sized players (51-200 employees) and start-ups / small players (2-50 employees), which collectively represent more than 80% of the total contract manufacturers. In addition, it is important to mention that about 33% of the firms were founded post 2010. Approximately 60% of the players carry out manufacturing operations across all scales of operation More than 60% of the service providers are engaged in manufacturing of recombinant proteins and peptides. This was followed by 49% CMOs that claim to have the required capabilities to provide antibody manufacturing services. It is worth mentioning that a number of biologic manufacturers in this domain have the required capabilities to provide manufacturing services for niche and upcoming classes of biologics, such as ADCs, cell therapies, gene therapies and plasmid DNA. 450+ manufacturing facilities dedicated to biologic-based therapies have been established globally North America has emerged as a key manufacturing hub for biotherapeutics, featuring the presence of nearly 33% of the total manufacturing facilities. This is followed by facilities located in Europe and Asia-Pacific. Prominent manufacturing hubs within Europe include (in decreasing order of number of facilities) Germany, the UK, France, Italy and Spain. 800 partnerships were established in this domain, during the period 2015-2022 Partnership activity of biologic contract manufacturers has increased at a CAGR of 42%, during the given period. Manufacturing agreements emerged as the most popular type of partnership model adopted by industry stakeholders (37%), followed by product development and manufacturing agreements (19%). Further, over 80% of the expansion projects undertaken by industry stakeholders were initiated since 2020. Currently, 54% of the overall, installed biopharmaceutical contract manufacturing capacity is for mammalian expression systems The maximum (49%) capacity is installed with players companies based in Asia-Pacific. It is worth mentioning that the aforementioned region has a higher number of players engaged in biopharmaceutical contract manufacturing, which have further established multiple production facilities. This is followed by the capacity available with players having headquarters in North America (25%) and Europe (24%). For additional details, please visit https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html You may also be interested in the following titles: 1. Peptide Therapeutics: Contract API Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035 2. Biopharmaceutical Excipient Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035 Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com

The pharmaceutical secondary packaging market is projected to grow at an annualized rate of 7.6% during the period 2022-2035, claims Roots Analysis In order to avail benefits, such as higher flexibility, reduced cost and assistance in meeting the rising demands, several pharmaceutical companies have demonstrated a preference to outsource their secondary packaging requirements to contract packaging organizations. Roots Analysis has announced the addition of “Pharmaceutical Secondary Packaging Market, 2022 – 2035” report to its list of offerings. The anticipated growth in the therapeutics pipeline is likely to translate into a significant rise in the demand for cost-effective and quality secondary packaging solutions, presenting lucrative opportunities for contract packaging organisations. Driven by the growth of the overall pharmaceutical industry and increasing preference of drug developers for outsourcing certain operations, the secondary packaging providers market is expected to witness a steady increase. Driven by the ongoing innovation in this field, continuous growth in the pharmaceutical drugs pipeline and a steady rise in drug approvals, the pharmaceutical secondary packaging market is likely to witness positive growth in the foreseen future. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/pharmaceutical-secondary-packaging-market/request-sample.html Key Market Insights Around 165 companies claim to offer pharmaceutical secondary packaging services, globally Majority (51%) of the industry stakeholders are headquartered in Europe, followed by those based in North America (37%) and Asia-Pacific (12%). In addition, close to 65% of the secondary packaging providers offer cartons, followed by companies offering boxes (53%) and other packaging formats, such as trays and pouches (29%). Partnership activity has grown at an annualized rate of ~85%, between 2018-2021 Maximum number of partnerships were observed in 2020 (29), indicating a recent increase in the partnership activity in this domain. Majority of these agreements were reported to be instances of acquisitions, representing over 45% of the total number of instances. Expansion activity in this domain has grown at a CAGR of ~55%, between 2018 and 2022 Most of such initiatives were focused on expanding the existing capacity (40%), followed by instances of establishing a new facility (38%) and facility expansions (13%). Further, majority of the investments were made in facilities located in North America (54%) and Europe (35%). Till 2035, annual demand for pharmaceutical packaging solutions is expected grow at a CAGR of ~8% Currently, Asia-Pacific and North America capture the majority share of the overall demand for pharmaceutical secondary packaging (~70%). By 2035, the demand for secondary packaging products is projected to reach over 200 billion units. Further, currently, the highest demand (95%) is generated via secondary packaging of vials and bottles. North America and Europe are anticipated to capture close to 60% of the market share, by 2035 In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace (6.2%) in the long term. Further, in 2035, majority share (~95%) of the pharmaceutical secondary packaging revenues is likely to be generated from packaging of vials and bottles. For additional details, please visit https://www.rootsanalysis.com/reports/pharmaceutical-secondary-packaging-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com

The site management organizations (SMO) market is projected to grow at an annualized rate of ~10% during the period 2021-2035, claims Roots Analysis The rapidly growing clinical pipeline and challenges associated with the conduct of clinical trials in a cost and time effective manner, has presented lucrative opportunities for service providers with expertise in clinical trial site management Roots Analysis has announced the addition of “Site Management Organizations (SMO) Market, 2021 – 2035” report to its list of offerings In recent years, drug / device developers have demonstrated a preference to continue relying on SMOs for conducting clinical trials in order to significantly optimize trial cost and research timelines. Driven by the steady growth in clinical research activity and inherent benefits offered by Site management organizations (SMO), the market opportunity for such players is projected to grow at a significant pace in the foreseen future. Key Market Insights Around 250 companies across the world claim to offer clinical trial site management services Majority (43%) of the industry stakeholders are headquartered in North America, followed by those based in Asia-Pacific (32%) and Europe (19%). In addition, 25% of the companies engaged in this domain offer site management services across the globe, followed by those providing services in Asia-Pacific (23%). 200+ partnerships were established in this domain, during the period 2016-2021 Service alliances (26%) and clinical trial agreements (23%) emerged as the most common types of partnership models adopted by stakeholders engaged in this domain. Nearly 65% of the deals in this domain were established after 2018, with the maximum activity being reported in 2021 (56). ~USD 1 billion invested in various domain focused initiatives, since 2015 Maximum number of funding instances (21%) were reported in 2021, amounting to USD 614 million in capital investments. A significant number of funding instances (43%) were venture capital rounds, followed by instances of other equity (29%) and grants (7%). Till 2035, annual demand for clinical trial study participants is expected grow at a CAGR of 8.2% Currently, North America and Asia-Pacific hold the majority share of the overall demand for clinical trial study participants (60%). By 2035, the demand for patients in clinical trial studies is projected to reach 25 million. Further, currently, the highest demand is generated via phase III trials (43%), followed by phase IV studies (38%). North America and Europe are anticipated to capture close to 65% of the market share, by 2035 In addition, in Asia-Pacific the Site Management Organization Market Growth is likely to be at a relatively faster pace (9%) in the long term. Further, in 2035, the majority share (~45%) of clinical trial site management revenues is likely to be generated from trials focused on phase III evaluation of clinical studies. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/site-management-organizations-market/request-sample.html For additional details, please visit https://www.rootsanalysis.com/reports/site-management-organizations-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Patient Recruitment and Retention Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030 2. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com

SINGLE-USE SENSORS FOR BIOPROCESSING MARKET– CURRENT AND FUTURE MARKET POTENTIAL The sensors can be classified based on the type of variables measured, which include chemical variables (pH, dissolved oxygen or substrate or product concentration), physical variables (temperature, pressure, or viscosity), and biological variables (biomass concentration/morphology or biomass productivity). Sensors are used to detect events or changes in environment parameters during a bioprocess control. These sensors can also be classified on the basis of different principles used for measuring the variables, such as electrochemical sensors, optical chemosensor systems (known as optodes), optical spectroscopic sensors, and calorimetric sensors. Further, sensors can be classified on the basis of their placement and integration within the bioreactor. sensors and controllers can be submerged in a liquid phase inside the bioreactor, submerged in a gas phase inside the bioreactor, in the exhaust gas stream, or placed with no physical connection to the bioreactor. Based on the abovementioned classification the sensors can be broadly categorized as follows:  At-line Sensors: These types of sensors provide data obtained by procedures performed after a short delay in the sampling and analysis. In case of filtration for high-performance liquid chromatography analysis and derivatization for gas chromatography, analytes are accessible after pre-treatment only.  In-line sensors (known as in situ sensors): These sensor types are in direct contact with the process, either with the liquid or gas phase. These help in providing data of the bioprocess in an online format. Single-use sensors offer a number of benefits, such as ease of use, and convenience components, while providing the accuracy and robustness of traditional measurement techniques. Further improvements in analytical equipment, sensors and probes may facilitate process quantification and process analytical technology (PAT). Therefore, as bioprocessing processes becomes increasingly monitored by improved and novel detection methods (chemical, physical, and microbiological) and assays including single-use sensors, the output obtained can be further used for mathematical modeling and risk analysis. The key advantages associated with SUT include reduced risk of cross-contamination, lower capital expenditure, and flexibility. Single-use bioprocessing systems are known to significantly reduce operation and manufacturing costs along with maintaining the overall quality of the product. The major advantages offered by single-use technologies are listed below:  Cost Reduction  Increased Productivity  Easy Disposal  Less Energy and Water Demand  Time Saving  Reduced Risk of Cross-Contamination For additional details, please visit https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html You may also be interested in the following titles: 1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition), 2021-2030 2. Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition), 2020-2030 3. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030 Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/